CRF Announces TCT 2021 Late-Breaking Trials and Science

Annual Scientific Symposium Will Take Place November 4-6, 2021

NEW YORK – September 16, 2021 – The Cardiovascular Research Foundation (CRF) has announced 22 late-breaking trial and science presentations that will be reported at TCT 2021. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. It will take place November 4-6, 2021 in Orlando, Florida at the Orange County Convention Center and simultaneously broadcast live.

“Every year, TCT features groundbreaking research in interventional cardiovascular medicine that directly impacts patient care and how physicians treat heart disease,” said Juan F. Granada, MD, President and Chief Executive Officer of CRF. “We are excited to be back in person to present a series of exciting new data that will continue pushing the field forward by improving procedures and identifying the types of patients who would benefit most from treatment.”

The studies selected examine the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices that demonstrate potential to treat or prevent cardiovascular disease. Late-breaking trials and science will be presented in the Clinical Science Theater and highlighted during press conferences scheduled for Thursday, November 4; Friday, November 5; and Saturday, November 6.

The Program Guide can be found here:https://tct2021.crfconnect.com/program-guide. Media are invited to attend TCT in person or online and can apply for media credentials at:https://tct2021.crfconnect.com/press-registration.

Thursday, November 4, 2021

Late-Breaking Trials

• FAME 3: A Randomized Trial of FFR-Guided Stenting Compared With CABG
• FAVOR III China: A Sham-Controlled Randomized Trial Comparing QFR-Guided and Angiography-Guided PCI
• SUGAR: A Randomized Trial of Amphilimus-eluting Stents and Zotarolimus-eluting Stents in Patients With Diabetes

Late-Breaking Science

• OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG
• EROSION III: A Randomized Trial of OCT-Guided Intervention in STEMI Patients With Early Infarct Artery Patency
• RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration
• iFR-SWEDEHEART: Five-Year Outcomes of a Randomized Trial of iFR-Guided vs. FFR-Guided PCI

Friday, November 5, 2021

Late-Breaking Trials

• SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk
• PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk
• CHOICE-CLOSURE: A Randomized Trial of Plug-Based Versus Suture-Based Large-Bore Vascular Closure

Late-Breaking Science

• AMULET IDE: One-Year Device Closure and Device-Related Thrombus Outcomes From a Randomized Trial of Amulet versus Watchman for Left Atrial Appendage Occlusion
• PRAGUE-17: Three-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure Versus Direct Acting Oral Anticoagulation in Patients With Atrial Fibrillation
• MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk Presenter
• STOPDAPT-2 Total Cohort: Pooled Results From Two Randomized Trials of Clopidogrel Monotherapy After 1-Month DAPT Following PCI According to ACS Presentation and Ischemic and Bleeding Risk

Saturday, November 6, 2021

Late-Breaking Trials

• SWISS-APERO: A Randomized Trial of the Amulet Versus Watchman FLX Devices for Left Atrial Appendage Closure
• OPT-PEACE: A Double-blind Randomized Trial of the Effect of Different Antiplatelet Regimens on Gastrointestinal Injury
• GUIDE-HF: A Randomized Trial of Hemodynamic-Guided Management of Heart Failure – Outcomes According to Ejection Fraction

Late-Breaking Science

• A Randomized Trial of Sirolimus-coated Versus Paclitaxel-coated Balloons in De Novo Coronary Lesion
• BIO-RISE CHINA: A Randomized Trial of a Biolimus-Coated Balloon Versus POBA in Small Vessel Coronary Artery Disease
• One-year Outcomes of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-Coated Balloons Versus POBA in Coronary In-Stent Restenosis Lesions
• Intrepid TMVR Early Feasibility: Thirty-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement
• TRISCEND: Six-Month Outcomes of Transfemoral Tricuspid Valve Replacement in Patients With Tricuspid Regurgitation

Receive updates on Twitter at http://twitter.com/TCTConference and http://twitter.com/crfheart.

About CRF

The Cardiovascular Research Foundation (CRF) is one of the world’s leading nonprofit organizations specializing in interventional cardiology innovation, research, and education. CRF is dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For nearly 30 years, CRF has helped pioneer medical advances and educated doctors on the latest treatments for heart disease. CRF is comprised of the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the premier educational meeting specializing in interventional cardiovascular medicine. Now in its 33^rd year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit www.crf.org and www.tctconference.com.